Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Chemotherapy and Radiotherapy
- Gastrointestinal Cancer
- Neoadjuvant Therapy
- Paediatric Cancers
- Prostate Cancer
- Colon Cancer
- Adjuvant Therapy
- Blood Cancer
Abstract
Citation: Clin Oncol. 2023;8(1):2028.DOI: 10.25107/2474-1663.2028
Differential Expression of PP2A and Set in Hepatocellular Carcinoma: Antitumoral Effect of an Interfering Peptide Blocking the Interaction
Rachid Boudjelloul, Angelita Rebollo, Severine Loisel, Frederic Charlotte, Jean Francois Franetich and Eric Savier
UTCBS, Inserm U1267, Faculty of Pharmacy, Paris Cite University, Paris, France
Common Animal Shop, University of Brest, F-29238 Brest, France
Department of Pathological Anatomy, Public Assistance - Paris Hospitals, Pitié Salpêtrière, Paris, France
Cimi, Faculty of Medicine, Sorbonne University, France
Department of Hepato-Bilio-Pancreatic Surgery, Liver Transplantation, Public Assistance - Paris Hospitals, Pitié Salpêtrière, Sorbonne University, Paris, France
Saint Antoine Research Center, Sorbonne University, Inserm, Paris, France
*Correspondance to: Angelita Rebollo
PDF Full Text Research Article | Open Access
Abstract:
Hepatocellular carcinoma is one of the most frequent cancers worldwide. Systemic treatments such as immune checkpoint or tyrosine kinase inhibitors have some efficacy but also have many adverse effects. More specifically targeted therapies are therefore needed. In this study, we investigated the anti-tumoral effect of a tumor penetrating and interfering peptide blocking the interaction between the proteins PP2A and SET. We analyzed the expression of two proteins, the phosphatase PP2A and the oncoprotein SET, in a group of samples from 21 liver cancer patients with different aggressiveness scores. Expression of PP2Aand SET was found to correlate with aggressiveness of the tumor. In vivo tests on xenograft models of hepatocellular carcinoma xenograft models showed an anti-tumoral effect of iRGD-IP, a tumor-penetrating and interfering peptide that blocks PP2A/ SET interaction and specifically targets tumor cells suggesting that this peptide could be a strong candidate for development as therapeutic peptide for liver tumor treatment.
Keywords:
Therapeutic peptide; Liver cancer; Xenograft models; PP2A; SET
Cite the Article:
Boudjelloul R, Rebollo A, Loisel S, Charlotte F, Franetich JF, Savier E. Differential Expression of PP2A and Set in Hepatocellular Carcinoma: Antitumoral Effect of an Interfering Peptide Blocking the Interaction. Clin Oncol. 2023;8:2028..